Able interim CEO walks as FDA sends in 483
Ailing US generics company Able Laboratories lost its second chief executive in six weeks on Friday, after Richard Mauro tendered his resignation.
Archives for July 11, 2005
Finding sheds light on drug toxicity
Researchers in the US have uncovered the mechanism underlying a genetic tendency for some patients to be more susceptible to side effects of drugs than others.
Applied Bio, Invitrogen forge proteomics alliance
Applied Biosystems has teamed up with Invitrogen to combine forces on providing proteomic analyses and biomarker studies in drug discovery and disease research.
AstraZeneca licenses cholesterol drug class from Avanir
AstraZeneca has forged a deal with US biotechnology company Avanir Pharmaceuticals - valued at up to $340 million - for the development of a new type of treatment for high cholesterol that could be more effective than current drugs in treating...
Roche, GE link up on personalised medicine
Roche and GE Healthcare have entered into a collaboration aimed at developing a personalised care strategy for patients with Alzheimer's disease.
Proteus offers services to 3rd parties
French biotechnology company Proteus is launching a business unit to provide protein engineering and production services for the life science industry.